Pattern Discovery Engines™ accurately detect increasing number of diseases in 3 seconds using 2 drops of saliva
REDMOND, WA, APRIL 6, 2023 — Pattern Computer®, Inc. (Pattern) is pleased to announce that Cellus Group and Pattern are collaborating to test Pattern’s innovative, portable AI/ML device to accurately detect key respiratory diseases in 3 seconds using 2 drops of saliva (including Covid-19, RSV, Influenza, Rhinovirus, and others.)
Pattern has developed a novel diagnostic research instrument, ProSpectral™, that dramatically improves the speed and availability of testing respiratory diseases with the same accuracy as PCR tests.
ProSpectral offers a unique combination of improvements over existing test systems:
• 3-second time-to-results (TTR) enables vastly faster diagnosis, boosting patient throughput and satisfaction
• Exceptional balanced accuracy of 98.5% matches that of PCR tests
• NO reagents are required – no toxic waste for facility to handle and dispose of
• Only 2 drops of saliva required – no invasive, unpleasant nasopharyngeal swabs
• Small and portable (shoe box-sized and < 8lbs) – perfect for mobile testing
• Can process 1200 samples per hour
• Very simple operation, training, and maintenance – no medical licensure required
• Detecting new diseases and variants only requires a remote software update
• Much less expensive than other tests requiring reagents and complex equipment
Cellus Group in 2022 completed studies to support initial validation of ProSpectral’s data modelling. It will now begin further studies and gather 2,000 fresh samples, scan them with ProSpectral, and test them for viral cross-specificity. This will contribute to finalizing ProSpectral’s initial disease modelling and eventual design of clinical trials.
The technology ProSpectral uses is fundamentally different from current relevant technologies for respiratory disease detection. Pattern’s solution leverages advanced spectrophotometry combined with highly advanced AI/ML analytics.
ProSpectral allows for vastly faster diagnosis, boosting patient throughput and satisfaction. It enables fast, easy point-of-entry screening of staff/patients/visitors at hospitals, clinics, schools, businesses, transportation to protect operational capability. It is also ideal for mobile testing at indoor or outdoor locations with little infrastructure.
About Cellus Group, a Chilean biotechnology multinational with a site in León-Spain,
Collaborating in the development of ProSpectral in one of the Cellus Groups’ important initiatives as a leader in supporting and bringing to market innovations in biotechnology. Cellus plans to offer ProSpectral’s unique capabilities and efficiencies to hospital and clinic clients across Latin America, Spain, and beyond.
Cellus Contacts:
Francisco Aulestia, CTO, CELLUS GROUP francisco.aulestia@cellus.cl
Rodrigo Arancibia, CEO / Founder CELLUS GROUP, rodrigo.arancibia@cellus.cl
About Pattern Computer®, Inc. www.patterncomputer.com
Pattern, based in Seattle with offices worldwide, consists of a multi-disciplinary team with advanced degrees and/or successful careers in biology, microbiology, bioinformatics, mathematics, physics, software, hardware, and electronics. Over the past 4 years, it has quietly invented a unique mathematical analysis and machine learning engine, the Pattern Discovery Engine™ (PDE) that can discover new patterns in complex, high-dimensional data. Critically, it provides explanation of ‘how’ the patterns were discovered, with a mathematical model that can be leveraged to better understand what can be changed to become more efficient and effective.
In medical diagnostics, the Pattern Discovery Engine™ has enabled creating a small, portable, multiplex device, ProSpectral, that can detect Covid-19 and other diseases with 3-second TTR and PCR level accuracy – using no reagents. This will enable dramatic improvement in Point-of Care operational throughput and efficiency.
Other applications of the PDE are also underway in genomics and drug therapy discoveries or combinations for several cancers including triple-negative breast, ovarian, colorectal, prostate, and eventually lung cancer. These include active collaborations with well-known institutions including the Lawrence Berkeley National Laboratory, the J. Craig Venter Institute (JCVI), Los Alamos National Laboratory, the Fred Hutch Cancer Center, the University of Washington and the University of California at San Diego.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.
CONTACT: Denyse Hudson – 360-298-0658 – Denyse@PatternComputer.com
Copyright © 2023 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, Pattern, and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.